Interested in training for your team? Click here to learn more

In-Licensing and Out-Licensing in the Pharmaceutical Industry

Evaluating and Conducting Due Diligence of Product and Licensing Partner; Negotiating and Structuring Term Sheet and Agreements

Recording of a 90-minute premium CLE video webinar with Q&A

This program is included with the Strafford CLE Pass. Click for more information.
This program is included with the Strafford All-Access Pass. Click for more information.

Conducted on Thursday, February 22, 2024

Recorded event now available

or call 1-800-926-7926

This CLE webinar will guide IP counsel on in-licensing and out-licensing in the pharmaceutical industry. The panel will discuss the advantages and disadvantages of both as well as the key considerations when weighing whether to use either type. The panel will also address the evaluation of the product and licensing partner and the due diligence process. The panel will offer best practices for structuring the agreement.

Description

Pharmaceutical companies often explore partnership opportunities. A company may seek to acquire the rights to another organization's product or IP to expand its portfolio or enter new markets (in-licensing) Similarly, pharma companies may grant another company the right to use its technology or IP (out-licensing).

In both instances, it is critical for both the licensor and licensee to evaluate the product involved as well as the partner organization. Due diligence should be conducted and careful consideration should be given to the potential benefits and risks, from royalties to regulatory issues to the impact on product development with in-licensing and out-licensing. Also, the due diligence should look into inventorship, ownership, patentability/validity and freedom to operate.

Listen as our authoritative panel of patent attorneys examines the advantages and disadvantages of in-licensing and out-licensing and the key considerations when weighing whether to use either type from both the licensee's and licensor's perspective. The panel will also address the evaluation and due diligence of the product and licensing partner as well as term sheet and agreement negotiation and structuring.

READ MORE

Outline

  1. Advantages of in-licensing
  2. Advantages of out-licensing
  3. Key considerations
    1. Licensor
    2. Licensee
  4. Product and licensing partners
    1. Evaluation
    2. Due diligence
  5. Term sheets
  6. Structuring licensing agreements

Benefits

The panel will review these and other key issues:

  • What key considerations should pharma organizations and counsel weigh when determining whether to in- or out-license technology or products?
  • What steps can licensee counsel take to effectively build protections into the license itself?
  • What steps should licensor counsel take to mitigate the risks of licensing its technology?

Faculty

Barash, Eyal
Eyal H. Barash
Member
Barash Law

Mr. Barash specializes in legal services for emerging knowledge-based companies with a special emphasis in life science...  |  Read More

Irving, Thomas
Thomas L. Irving
Partner
The Marbury Law Group

Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution,...  |  Read More

O’Brien, Michelle
Michelle E. O'Brien
Partner
The Marbury Law Group

Ms. O’Brien has more than 20 years of experience representing domestic and foreign clients of all sizes in...  |  Read More

Access Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include course handouts.

To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video

Download